These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10795342)

  • 1. Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention.
    Bartell SM; Ponce RA; Takaro TK; Zerbe RO; Omenn GS; Faustman EM
    Risk Anal; 2000 Feb; 20(1):87-99. PubMed ID: 10795342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in understanding the biomolecular basis of chronic beryllium disease: a review.
    McCleskey TM; Buchner V; Field RW; Scott BL
    Rev Environ Health; 2009; 24(2):75-115. PubMed ID: 19658317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.
    Maier LA; McGrath DS; Sato H; Lympany P; Welsh K; Du Bois R; Silveira L; Fontenot AP; Sawyer RT; Wilcox E; Newman LS
    J Immunol; 2003 Dec; 171(12):6910-8. PubMed ID: 14662898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease.
    Lombardi G; Germain C; Uren J; Fiorillo MT; du Bois RM; Jones-Williams W; Saltini C; Sorrentino R; Lechler R
    J Immunol; 2001 Mar; 166(5):3549-55. PubMed ID: 11207315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease.
    Gaede KI; Amicosante M; Schürmann M; Fireman E; Saltini C; Müller-Quernheim J
    J Mol Med (Berl); 2005 May; 83(5):397-405. PubMed ID: 15750822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-DPB1 and chronic beryllium disease: a HuGE review.
    McCanlies EC; Kreiss K; Andrew M; Weston A
    Am J Epidemiol; 2003 Mar; 157(5):388-98. PubMed ID: 12615603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease.
    Weston A; Ensey J; Kreiss K; Keshava C; McCanlies E
    Am J Ind Med; 2002 Jun; 41(6):457-65. PubMed ID: 12173370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization.
    McCanlies EC; Ensey JS; Schuler CR; Kreiss K; Weston A
    Am J Ind Med; 2004 Aug; 46(2):95-103. PubMed ID: 15273960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical considerations in testing workers for the -Glu69 marker of genetic susceptibility to chronic beryllium disease.
    Silver K; Sharp RR
    J Occup Environ Med; 2006 Apr; 48(4):434-43. PubMed ID: 16607200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease.
    Maier L; Martyny J; Mroz M; McGrath D; Lympany P; duBois R; Zhang L; Murphy J; Newman LS
    Chest; 2002 Mar; 121(3 Suppl):81S. PubMed ID: 11893702
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles.
    Wang Z; White PS; Petrovic M; Tatum OL; Newman LS; Maier LA; Marrone BL
    J Immunol; 1999 Aug; 163(3):1647-53. PubMed ID: 10415070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
    Richeldi L; Sorrentino R; Saltini C
    Science; 1993 Oct; 262(5131):242-4. PubMed ID: 8105536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69.
    Amicosante M; Sanarico N; Berretta F; Arroyo J; Lombardi G; Lechler R; Colizzi V; Saltini C
    Hum Immunol; 2001 Jul; 62(7):686-93. PubMed ID: 11423174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of sensitivity to beryllium in mice.
    Tarantino-Hutchison LM; Sorrentino C; Nadas A; Zhu Y; Rubin EM; Tinkle SS; Weston A; Gordon T
    J Immunotoxicol; 2009 Jun; 6(2):130-5. PubMed ID: 19589099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing.
    Judd NL; Griffith WC; Takaro T; Faustman EM
    Risk Anal; 2003 Dec; 23(6):1211-20. PubMed ID: 14641896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals.
    Sato H; Spagnolo P; Silveira L; Welsh KI; du Bois RM; Newman LS; Maier LA
    Tissue Antigens; 2007 Dec; 70(6):480-6. PubMed ID: 17927685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beryllium sensitivity is linked to HLA-DP genotype.
    Wang Z; Farris GM; Newman LS; Shou Y; Maier LA; Smith HN; Marrone BL
    Toxicology; 2001 Aug; 165(1):27-38. PubMed ID: 11551429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity.
    Rossman MD; Stubbs J; Lee CW; Argyris E; Magira E; Monos D
    Am J Respir Crit Care Med; 2002 Mar; 165(6):788-94. PubMed ID: 11897645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity.
    Rosenman KD; Rossman M; Hertzberg V; Reilly MJ; Rice C; Kanterakis E; Monos D
    Occup Environ Med; 2011 Jul; 68(7):487-93. PubMed ID: 21186201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and exposure risks for chronic beryllium disease.
    Maier LA
    Clin Chest Med; 2002 Dec; 23(4):827-39. PubMed ID: 12516537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.